3-Amino-5-(4-fluoro-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one | 253324-65-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3-Amino-5-(4-fluoro-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one
• 英文别名: 3-Amino-1,3-dihydro-1-methyl-5-(4-fluorophenyl)-2H-1,4-benzodiazepin-2-one；1,3-dihydro-1-methyl-3-amino-5-(4-fluorophenyl)-2H-1,4-benzodiazepine-2-one；3-amino-2,3-dihydro-1-methyl-5-(4-fluorophenyl)-1H-1,4-benzodiazepin-2-one；3-amino-5-(4-fluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
• CAS: 253324-65-1
• 化学式: C₁₆H₁₄FN₃O
• 分子量: 283.305
• InChiKey: JPDZDCXSGWQKPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Amino-5-(4-fluoro-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 以92%的产率得到{1-[5-(4-Fluoro-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamoyl]-3-methyl-butyl}-carbamic Acid tert-Butyl Ester
  参考文献：
  名称：

  Amino lactam sulfonamides as inhibitors of A&bgr; protein production

  摘要：

  本发明涉及具有式（I）的新型内酰胺，其药物组成物和使用方法。这些新化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ-肽的产生，从而防止神经沉积物的淀粉样蛋白质形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。

  公开号：

  US06503901B1

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production
  申请人：——

  公开号：US20020052360A1

  公开（公告）日：2002-05-02

  This invention relates to novel lactams having the formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式(I)的新颖内酰胺：1及其药物组合物及其使用方法。这些新颖化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ-肽的产生，从而防止神经系统中淀粉样蛋白沉积的形成。更具体地，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，如阿尔茨海默病和唐氏综合症。
• Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production
  申请人：——

  公开号：US20030166636A1

  公开（公告）日：2003-09-04

  This invention relates to novel lactams having the formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有公式(I)的新颖内酰胺：及其药物组合物及其使用方法。这些新颖化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ-肽的产生，从而防止神经性淀粉样蛋白沉积的形成。更具体地说，本发明涉及治疗与β-淀粉样蛋白产生相关的神经障碍，如阿尔茨海默病和唐氏综合症。
• Succinoylaminobenzodiazepines as inhibitors of Abeta protein production
  申请人：Olson E. Richard

  公开号：US20060025407A1

  公开（公告）日：2006-02-02

  This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  这项发明涉及具有以下结构式（I）的新型内酰胺，以及它们的药物组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ肽的产生，从而防止神经沉积物的淀粉样蛋白形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经疾病的治疗，如阿尔茨海默病和唐氏综合征。
• Formal [3+2] Cycloaddition Between in situ Formed 1,4‐Benzodiazepin‐2‐One‐Based Azomethine Ylides and Azodicarboxylic Acid Derivatives: Diastereoselective Synthesis of Spiro‐1,4‐Benzodiazepin‐2‐Ones
  作者：Xiao‐Zu Fan、Hui‐Hui Wu、Zhe Tang、Heng Zhang、Lu‐Yu Cai、Xiao‐Fan Bi、Hong‐Wu Zhao

  DOI：10.1002/adsc.202001486

  日期：2021.3.2

  In the presence of PhCO2H (20 mol%), the formal [3+2] cycloaddition between in situ formed 1,4‐benzodiazepin‐2‐one‐based azomethine ylides and azodicarboxylic acid derivatives proceeded readily, thus leading to the formation of trans‐configured spiro‐1,4‐benzodiazepin‐2‐ones in up to 98% chemical yield with >20:1 dr. The relative configuration of the title compounds was unambiguously determined by

  在存在PhCO 2 H（20 mol％）的情况下，原位形成的1,4-苯并二氮杂-2-2-酮基偶氮甲亚胺与偶氮二羧酸衍生物之间的正式[3 + 2]环加成反应很容易进行，从而导致形成的反式-型螺- 1,4-苯并二氮杂-2-酮在高达98％的化学产率> 20：1个 博士。标题化合物的相对构型是通过X射线单晶结构分析明确确定的。假设反应机理是考虑到了孤立的螺-1,4-苯并二氮杂-2--1-酮的非对映选择性形成。